Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Miltefosine). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Miltefos is a leishmaniacide used in adults and adolescents aged 12 and older who weigh at least 30 kg (66 lbs). It is prescribed to treat visceral leishmaniasis caused by *Leishmania donovani*; cutaneous leishmaniasis caused by *Leishmania braziliensis*, *Leishmania guyanensis*, or *Leishmania panamensis*; and mucosal leishmaniasis caused by *Leishmania braziliensis*.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Administer with food to help reduce stomach upset. For patients weighing 30 to 44 kg, take one 50 mg capsule twice a day for 28 days in a row. For patients weighing 45 kg or more, take one 50 mg capsule three times a day for 28 days in a row.
পার্শ্বপ্রতিক্রিয়া
Adverse effects reported in at least 2% of patients receiving miltefosine include nausea, vomiting, diarrhea, and headache, along with reduced appetite, dizziness, and abdominal pain. Itching and drowsiness have also been noted, as well as rises in liver enzyme (transaminase) and creatinine levels on blood tests.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Embryo-Fetal Toxicity. Do not use Miltefos in pregnant women. Get a urine or serum pregnancy test before starting therapy, and advise women of reproductive potential to use effective contraception. Reproductive Effects. Miltefos caused testicular atrophy and impaired fertility in male rats and impaired fertility in female rats. Patients should be told of these reproductive toxicities seen in animal studies and that its potential effects on human fertility have not been adequately evaluated. Renal Effects. Monitor serum creatinine during therapy and for 4 weeks after therapy ends. Hepatic Effects. Monitor transaminases and bilirubin during therapy. Gastrointestinal Effects. Encourage the patient to drink plenty of fluids. Thrombocytopenia. Monitor platelet count during therapy for visceral leishmaniasis. Absorption of Oral Contraceptives. If vomiting and/or diarrhea occur, advise the patient to use an alternative method of contraception. Stevens-Johnson Syndrome. Discontinue Miltefos if this occurs.